
Elihu H. Estey, MD, professor of medicine, University of Washington School of Medicine, Fred Hutchinson Cancer Research Center, discusses a potential change to the FDA approval process as it relates to Mylotarg (gemtuzumab ozogamicin).

Your AI-Trained Oncology Knowledge Connection!


Published: December 18th 2013 | Updated: